FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2071738334> ?p ?o ?g. }

• W2071738334 endingPage "278" @default.
• W2071738334 startingPage "269" @default.
• W2071738334 abstract "The association of sarcoidosis and immune thrombocytopenia (ITP) has rarely been investigated. The aim of the current retrospective study was to investigate the clinical and biological phenotypes and outcome of this association in a large series of recent patients. Twenty patients (50% men) were included. Median age at sarcoidosis and ITP diagnosis was 36 (range, 10-83 yr) and 38 (range, 21-83 yr) years, respectively. In 11 of 20 (55%) patients, sarcoidosis onset preceded ITP (median interval, 48 mo; range, 6-216 mo). In 5 of 20 (25%) patients, the 2 conditions occurred concomitantly. In 4 of 20 (20%) patients, ITP onset preceded sarcoidosis (median interval, 68 mo; range, 15-153 mo). In 4 cases, sarcoidosis and ITP were not concomitant, since 1 condition was cured before the other was declared. In 12 of 20 (60%) patients there was a simultaneous onset or relapse of both ITP and sarcoidosis. Sarcoidosis phenotype was characterized by an acute onset in 40% of patients. The visceral involvement included thoracic sites in 19 of 20 (95%) patients and extrathoracic sites in 16 of 20 (80%) patients. At ITP onset, median platelet count was 11 × 109/L (range, 3-90); 17 (85%) patients had a platelet count <30 × 109/L. Seven (35%) patients had a bleeding score >8 without visceral bleeding. Nineteen of the 20 (95%) patients were treated specifically for ITP. After the first-line therapy (prednisone at 1 mg/kg per day for at least 3 consecutive weeks in all patients; with IVIg in addition for 10 patients with severe bleeding score), 12 of 19 (63%) patients achieved a complete response, 6 (31.5%) had a partial response, and only 1 patient failed to respond. At the end of ITP follow-up (median, 70 mo; range, 12-142 mo), 18 (90%) patients achieved a complete response, 1 achieved a partial response, and 1 had no response. After a median follow-up of 105 months, 13 of 20 (65%) patients had persistent sarcoidosis requiring prolonged therapy, and thus sarcoidosis represented the main long-term concern. Main conclusions were 1) ITP presentation was usually severe, but response to treatment was favorable in almost all cases, with no death and no severe bleeding, in contrast with older reports, 2) sarcoidosis was remarkable for the high proportion of cases with an acute onset, a chronic course, and the need for prolonged prednisone therapy, 3) sarcoidosis and ITP onset and evolution were not always synchronous. Abbreviations: ALPS = autoimmune lymphoproliferative syndrome, CR = complete response to treatment, HCQ = hydroxychloroquine, ITP = immune thrombocytopenia, IVIg = intravenous immunoglobulin, NR = no response to treatment, PR = partial response to treatment." @default.
• W2071738334 created "2016-06-24" @default.
• W2071738334 creator A5008531719 @default.
• W2071738334 creator A5014786838 @default.
• W2071738334 creator A5015257157 @default.
• W2071738334 creator A5017064684 @default.
• W2071738334 creator A5028703971 @default.
• W2071738334 creator A5031127153 @default.
• W2071738334 creator A5036285321 @default.
• W2071738334 creator A5040762997 @default.
• W2071738334 creator A5049530249 @default.
• W2071738334 creator A5056136082 @default.
• W2071738334 creator A5057077290 @default.
• W2071738334 creator A5057811682 @default.
• W2071738334 creator A5063371313 @default.
• W2071738334 creator A5067119199 @default.
• W2071738334 creator A5068145736 @default.
• W2071738334 creator A5069373819 @default.
• W2071738334 creator A5086789335 @default.
• W2071738334 creator A5087318995 @default.
• W2071738334 date "2011-07-01" @default.
• W2071738334 modified "2023-10-16" @default.
• W2071738334 title "Association of Sarcoidosis and Immune Thrombocytopenia" @default.
• W2071738334 cites W1927719150 @default.
• W2071738334 cites W1965945697 @default.
• W2071738334 cites W1980329154 @default.
• W2071738334 cites W1984073642 @default.
• W2071738334 cites W1992119885 @default.
• W2071738334 cites W1998798872 @default.
• W2071738334 cites W1999261746 @default.
• W2071738334 cites W2022813794 @default.
• W2071738334 cites W2036186242 @default.
• W2071738334 cites W2053971702 @default.
• W2071738334 cites W2086320143 @default.
• W2071738334 cites W2086440318 @default.
• W2071738334 cites W2090215480 @default.
• W2071738334 cites W2094247103 @default.
• W2071738334 cites W2135178240 @default.
• W2071738334 cites W2149662253 @default.
• W2071738334 cites W2165779188 @default.
• W2071738334 cites W4210977201 @default.
• W2071738334 cites W4232025330 @default.
• W2071738334 doi "https://doi.org/10.1097/md.0b013e31822618b3" @default.
• W2071738334 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21694642" @default.
• W2071738334 hasPublicationYear "2011" @default.
• W2071738334 type Work @default.
• W2071738334 sameAs 2071738334 @default.
• W2071738334 citedByCount "23" @default.
• W2071738334 countsByYear W20717383342012 @default.
• W2071738334 countsByYear W20717383342013 @default.
• W2071738334 countsByYear W20717383342014 @default.
• W2071738334 countsByYear W20717383342015 @default.
• W2071738334 countsByYear W20717383342016 @default.
• W2071738334 countsByYear W20717383342017 @default.
• W2071738334 countsByYear W20717383342019 @default.
• W2071738334 countsByYear W20717383342020 @default.
• W2071738334 countsByYear W20717383342021 @default.
• W2071738334 countsByYear W20717383342022 @default.
• W2071738334 countsByYear W20717383342023 @default.
• W2071738334 crossrefType "journal-article" @default.
• W2071738334 hasAuthorship W2071738334A5008531719 @default.
• W2071738334 hasAuthorship W2071738334A5014786838 @default.
• W2071738334 hasAuthorship W2071738334A5015257157 @default.
• W2071738334 hasAuthorship W2071738334A5017064684 @default.
• W2071738334 hasAuthorship W2071738334A5028703971 @default.
• W2071738334 hasAuthorship W2071738334A5031127153 @default.
• W2071738334 hasAuthorship W2071738334A5036285321 @default.
• W2071738334 hasAuthorship W2071738334A5040762997 @default.
• W2071738334 hasAuthorship W2071738334A5049530249 @default.
• W2071738334 hasAuthorship W2071738334A5056136082 @default.
• W2071738334 hasAuthorship W2071738334A5057077290 @default.
• W2071738334 hasAuthorship W2071738334A5057811682 @default.
• W2071738334 hasAuthorship W2071738334A5063371313 @default.
• W2071738334 hasAuthorship W2071738334A5067119199 @default.
• W2071738334 hasAuthorship W2071738334A5068145736 @default.
• W2071738334 hasAuthorship W2071738334A5069373819 @default.
• W2071738334 hasAuthorship W2071738334A5086789335 @default.
• W2071738334 hasAuthorship W2071738334A5087318995 @default.
• W2071738334 hasBestOaLocation W20717383341 @default.
• W2071738334 hasConcept C126322002 @default.
• W2071738334 hasConcept C167135981 @default.
• W2071738334 hasConcept C2778720950 @default.
• W2071738334 hasConcept C2779384505 @default.
• W2071738334 hasConcept C2781301800 @default.
• W2071738334 hasConcept C2993327898 @default.
• W2071738334 hasConcept C71924100 @default.
• W2071738334 hasConcept C89560881 @default.
• W2071738334 hasConcept C90924648 @default.
• W2071738334 hasConceptScore W2071738334C126322002 @default.
• W2071738334 hasConceptScore W2071738334C167135981 @default.
• W2071738334 hasConceptScore W2071738334C2778720950 @default.
• W2071738334 hasConceptScore W2071738334C2779384505 @default.
• W2071738334 hasConceptScore W2071738334C2781301800 @default.
• W2071738334 hasConceptScore W2071738334C2993327898 @default.
• W2071738334 hasConceptScore W2071738334C71924100 @default.
• W2071738334 hasConceptScore W2071738334C89560881 @default.
• W2071738334 hasConceptScore W2071738334C90924648 @default.
• W2071738334 hasIssue "4" @default.

• next